Document Detail


Long term recombinant interferon alpha treatment in MS with special emphasis to side effects.
MedLine Citation:
PMID:  9345419     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Twenty relapsing-remitting (RR) clinically definite MS patients were treated with 9 MIU intramuscular recombinant interferon alpha-2a (rIFNA) (Roferon-A, Roche) (n = 12) or placebo (n = 8) every other day for 6 months and followed up for a further 6 months after stopping treatment. Numbers of active lesions at MRI and of patients with clinical-MRI signs of disease activity and lymphocyte interferon gamma production, which were decreased during treatment, returned to values similar to baseline and placebos after stopping treatment. rIFNA chronic therapy seems therefore needed in order to maintain drug efficacy. Side effect profile was monitored, too, for over 1 year in the same 20 patients plus 25 additional RR MS patients. Besides the typical side effects of type I interferon therapy (fever, fatigue, depression, lymphopenia, hepatic enzyme elevation), occurrence of serum autoAbs was noted in 30% patients (in 60% antinuclear and in 80% antithyroid autoAbs). In two patients rIFNA treatment was stopped, in one case for antithyroid autoAbs and hypothyroidism, in the other for antinuclear autoAbs and a five-fold increase of ALT. A careful monitoring of serum autoAbs and of signs of thyroid or liver damage must always precede and accompany longterm type I IFN therapy.
Authors:
L Durelli; M R Bongioanni; B Ferrero; D Imperiale; E Verdun; A Oggero; E Gentile; G B Bradac; M Bergui; L Bergamini; B Bergamasco
Related Documents :
15915059 - Quality-of-life evaluation in an interferon therapy after radical surgery in cutaneous ...
18432159 - Optimizing outcomes in patients with hepatitis c virus genotype 2 or 3.
18537189 - Entecavir therapy for lamivudine-refractory chronic hepatitis b: improved virologic, bi...
17882419 - Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients wit...
20514309 - Clinical efficacy of a 24-months course of lamivudine therapy in patients with hbeag ne...
20375729 - Tailoring treatment duration to 12 to 16 weeks in hepatitis c genotype 2 or 3 with rapi...
10937119 - Nasal reconstruction in the elderly patient. the case for not letting age determine met...
19339559 - Cost-effectiveness of accelerated perioperative care and rehabilitation after total hip...
21414749 - Femoral revision in hip resurfacing compared with large-bearing metal-on-metal hip arth...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Multiple sclerosis (Houndmills, Basingstoke, England)     Volume:  1     ISSN:  1352-4585     ISO Abbreviation:  Mult. Scler.     Publication Date:  1996 Jul 
Date Detail:
Created Date:  1997-12-12     Completed Date:  1997-12-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9509185     Medline TA:  Mult Scler     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  366-71     Citation Subset:  IM    
Affiliation:
Clinica delle Malattie del Sistema Nervoso, Universita di Torino, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Autoantibodies / immunology
Female
Follow-Up Studies
Humans
Interferon Type I, Recombinant / adverse effects,  therapeutic use*
Magnetic Resonance Imaging
Male
Multiple Sclerosis / drug therapy*,  immunology
Pilot Projects
Chemical
Reg. No./Substance:
0/Autoantibodies; 0/Interferon Type I, Recombinant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  CAMPATH-IH in multiple sclerosis.
Next Document:  Treatment of relapsing-remittent multiple sclerosis with recombinant human interferon-alfa-2a: desig...